The impact of piracetam and octreotide on hippocampal expression of BAX and BCL2 genes in pentylenetetrazole-induced epileptic rats

Document Type : Research Paper


1 Department of Biology, Faculty of Science, University of Mohaghegh Ardabili, Ardabil, Iran

2 Department of Bioinformatics, Faculty of Advanced Technologies, University of Mohaghegh Ardabili, Namin, Iran

3 Department of Basic Science, Faculty of Veterinary Medicine, Shahrekord University, Shahrekord, Iran



Objective: Piracetam and octreotide as nootropic and neuroprotective medicines were used in the epileptic rats to evaluate their impacts on the hippocampal expression of BAX and BCL2 genes.
Materials and Methods: Six experimental groups of adult rats were pretreated for 7 days as follows: two piracetam groups (30 and 100 mg/kg/day), two octreotide groups (50 and 100 mg/kg/day), positive control group (injected with diazepam, 2 mg/kg, single dose before pentylenetetrazole injection) and negative control group (injected with normal saline). Seizures were induced with a single injection of pentylenetetrazole (PTZ, 60 mg/kg) after pretreatments. Signs of resulted seizures were classified according to the Racine scale. The BAX and BCL2 transcripts were measured in the hippocampus by quantitative real-time PCR.
Results: A delayed onset time of the seizures (stage 1 of Racine scale) and shorter time of the tonic-clonic seizures (stage 5 of Racine's scale) were observed in the piracetam and octreotide groups as compared to negative control group (P<0.05). The BAX transcript was higher in the positive control and octreotide (100 mg/kg) groups than other groups (P<0.05). The BCL2 transcript was higher in the positive control, piracetam (100 mg/kg) and octreotide (100 mg/kg) groups than the negative control group (P<0.05). The BAX/BCL2 ratio was lower in the positive control and piracetam (30 and 100 mg/kg) groups than other groups (P<0.05).
Conclusion: BAX/BCl2 ratio as an indicator of progressive apoptosis was attenuated by the piracetam in the hippocampus of epileptic rats while useful effects of the octreotide are independent of BAX/BCl2.


  1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-82.
  2. Goldberg EM, Coulter DA. Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction. Nature Reviews Neuroscience 2013;14(5):337-49.
  3. Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug‐resistant epilepsy. Cochrane Database of Systematic Reviews 2020 (6).
  4. Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. The Lancet 2006;367(9516):1087-100.
  5. Brodtkorb E. Common imitators of epilepsy. Acta Neurologica Scandinavica 2013;127:5-10.
  6. Hughes JR. Absence seizures: a review of recent reports with new concepts. Epilepsy and Behavior 2009;15(4):404-12.
  7. Michael GE, O’Connor RE. The diagnosis and management of seizures and status epilepticus in the prehospital setting. Emergency Medicine Clinics 2011;29(1):29-39.
  8. Rana A, Musto AE. The role of inflammation in the development of epilepsy. Journal of Neuroinflammation 2018;15(1):1-12.
  9. Cohen PA, Zakharevich I, Gerona R. Presence of piracetam in cognitive enhancement dietary supplements. JAMA internal Medicine 2020;180(3):458-9.
  10. Méndez-Armenta M, Nava-Ruíz C, Juárez-Rebollar D, Rodríguez-Martínez E, Yescas Gómez P. Oxidative stress associated with neuronal apoptosis in experimental models of epilepsy. Oxidative Medicine and Cellular Longevity 2014; 2014:1-12.
  11. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Reviews 2005;11(2):169-82.
  12. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs. Drugs 2010;70(3):287-312.
  13. Tortiglione A, Minale M, Pignataro G, Amoroso S, DiRenzo G, Annunziato L. The 2-oxopyrrolidinacetamide piracetam reduces infarct brain volume induced by permanent middle cerebral artery occlusion in male rats. Neuropharmacology 2002;43(3):427-33.
  14. Klopp T, ed. Arzneimittel-Interaktionen (in German). In: Information AfP, editor 2010.
  15. Gøtzsche PC, Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database of Systematic Reviews 2008 ;(3):CD000193. doi: 10.1002/14651858.CD000193.pub3.
  16. Hovind P, Simonsen L, Bülow J. Decreased leg glucose uptake during exercise contributes to the hyperglycaemic effect of octreotide. Clinical Physiology and Functional Imaging 2010;30(2):141-5.
  17. Chen L, Wang L, Zhang X, Cui L, Xing Y, Dong L, et al. The protection by octreotide against experimental ischemic stroke: up-regulated transcription factor Nrf2, HO-1 and down-regulated NF-κB expression. Brain Research 2012;1475:80-7.
  18. Allen MP, Blake JF, Bryce DK, Haggan ME, Liras S, McLean S, et al. Design, synthesis and biological evaluation of 3-amino-3-phenylpropionamide derivatives as novel μ opioid receptor ligands. Bioorganic and Medicinal Chemistry Letters 2000;10(6):523-6.
  19. Solmaz V, Çınar BP, Yiğittürk G, Özlece HK, Eroglu HA, Tekatas A, et al. Neuroprotective effects of octreotide on diabetic neuropathy in rats. Biomedicine and Pharmacotherapy 2017;89:468-72.
  20. Dundar S, Kalkan E, Keskin F, Kaya B, Erdi F, Yerlikaya FH, et al. The Effects of Octreotide Acetate on Spinal Cord Ischemia/Reperfusion Injury. Neurosurgery Quarterly. 2015;25(4):541-6.
  21. Kaviani M, Keshtkar S, Azarpira N, Aghdaei MH, Geramizadeh B, Karimi MH, et al. Cytoprotective effects of olesoxime on isolated human pancreatic islets in order to attenuate apoptotic pathway. Biomedicine and Pharmacotherapy 2019;112:108674.
  22. Pirany N, Bakrani Balani A, Hassanpour H, Mehraban H. Differential expression of genes implicated in liver lipid metabolism in broiler chickens differing in weight. British Poultry Science 2020;61(1):10-6.
  23. Hassanpour H, Bahadoran S, Neidaripour F, Ehsanifar N, Tavasolifar I, Madreseh S. Brain renin-angiotensin system in broiler chickens with cold-induced pulmonary hypertension. British Poultry Science 2019;60(5):499-505.
  24. Hassanpour H, Nikoukar Z, Nasiri L, Bahadoran S. Differential gene expression of three nitric oxide synthases is consistent with increased nitric oxide in the hindbrain of broilers with cold-induced pulmonary hypertension. British Poultry Science 2015;56(4):436-42.
  25. Sivalingam K, Samikkannu T. Neuroprotective effect of piracetam against Cocaine-induced neuro epigenetic modification of DNA methylation in astrocytes. Brain Sciences 2020;10(9):611.
  26. Kulsoom B, Shamsi TS, Afsar NA, Memon Z, Ahmed N, Hasnain SN. Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy? Cancer Management and Research 2018;10:403.
  27. Abdel-Salam OM, Hamdy SM, Seadawy SAM, Galal AF, Abouelfadl DM, Atrees SS. Effect of piracetam, vincamine, vinpocetine, and donepezil on oxidative stress and neurodegeneration induced by aluminum chloride in rats. Comparative Clinical Pathology 2016;25(2):305-18.
  28. Verma DK, Gupta S, Biswas J, Joshi N, Singh A, Gupta P, et al. New therapeutic activity of metabolic enhancer piracetam in treatment of neurodegenerative disease: Participation of caspase independent death factors, oxidative stress, inflammatory responses and apoptosis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 2018;1864(6):2078-96.
  29. Zaitone SA, Abo-Elmatty DM, Elshazly SM. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Indian Journal of Pharmacology 2012;44(6):774.
  30. Al-Shorbagy M, Nassar NN. Octreotide ameliorates inflammation and apoptosis in acute and kindled murine PTZ paradigms. Naunyn-Schmiedeberg's Archives of Pharmacology 2017;390(1):61-8.
  31. Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World Journal of Gastroenterology 2011;17(3):313.
  32. Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocrine-Related Cancer 2006;13(3):955-62.
  33. Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, et al. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. Journal of Neurosurgery 2016;127(3):660-9.